Boston Scientific Co. (BSX) Position Boosted by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 7,922.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,978,846 shares of the medical equipment provider’s stock after buying an additional 11,829,528 shares during the period. Oregon Public Employees Retirement Fund owned 0.87% of Boston Scientific worth $339,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Brasada Capital Management LP bought a new position in Boston Scientific during the fourth quarter worth $442,000. Parallel Advisors LLC boosted its position in Boston Scientific by 19.0% during the fourth quarter. Parallel Advisors LLC now owns 3,310 shares of the medical equipment provider’s stock worth $116,000 after purchasing an additional 528 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in Boston Scientific by 23.8% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 35,074 shares of the medical equipment provider’s stock worth $1,240,000 after purchasing an additional 6,744 shares during the period. Rhenman & Partners Asset Management AB boosted its position in Boston Scientific by 11.8% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 377,908 shares of the medical equipment provider’s stock worth $13,355,000 after purchasing an additional 39,940 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its position in Boston Scientific by 21.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 7,532 shares of the medical equipment provider’s stock worth $266,000 after purchasing an additional 1,320 shares during the period. Institutional investors and hedge funds own 91.60% of the company’s stock.

Shares of Boston Scientific stock opened at $39.79 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market capitalization of $54.63 billion, a price-to-earnings ratio of 27.07, a P/E/G ratio of 2.30 and a beta of 0.83. Boston Scientific Co. has a one year low of $25.84 and a one year high of $40.33.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.02. The business had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.57 billion. Boston Scientific had a return on equity of 26.80% and a net margin of 17.01%. The business’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.34 EPS. As a group, equities analysts expect that Boston Scientific Co. will post 1.56 EPS for the current fiscal year.

A number of equities analysts have commented on BSX shares. BTIG Research reaffirmed a “buy” rating and set a $45.00 price objective on shares of Boston Scientific in a research report on Tuesday, October 16th. Cowen set a $42.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Monday, October 22nd. Oppenheimer set a $38.00 target price on shares of Boston Scientific and gave the company a “hold” rating in a research report on Wednesday, October 24th. Canaccord Genuity upped their price objective on shares of Boston Scientific from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, October 25th. Finally, Argus upped their price objective on shares of Boston Scientific from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Friday, October 26th. Three equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $40.54.

In other Boston Scientific news, SVP Maulik Nanavaty sold 23,458 shares of Boston Scientific stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $37.28, for a total value of $874,514.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $38.15, for a total value of $190,750.00. Following the completion of the transaction, the executive vice president now directly owns 29,201 shares in the company, valued at $1,114,018.15. The disclosure for this sale can be found here. Insiders sold a total of 91,724 shares of company stock worth $3,350,373 over the last ninety days. Insiders own 0.73% of the company’s stock.

WARNING: “Boston Scientific Co. (BSX) Position Boosted by Oregon Public Employees Retirement Fund” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2019/02/13/boston-scientific-co-bsx-position-boosted-by-oregon-public-employees-retirement-fund.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: The Discount Rate – What You Need to Know

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply